Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003388 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00003388 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 38 participants.
The verdict
NCT00003388, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in treating patients with AIDS-related lymphoma.
Interventions
- DRUG cyclophosphamide
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG methotrexate
- BIOLOGICAL filgrastim
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 1999-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003388
The ClinicalTrials.gov registry entry for NCT00003388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003388 about?
NCT00003388 is a clinical study titled "Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin, cyclo...
What is the current status of trial NCT00003388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 1999-07-26.
What interventions are being tested in trial NCT00003388?
The interventions under investigation include: cyclophosphamide (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG), methotrexate (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00003388?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.